Recent developments in HIV protease inhibitor therapy.
Molla
A
A
Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL 60064, USA. akhter.m.molla@abbott.com
Granneman
G R
GR
Sun
E
E
Kempf
D J
DJ
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000378:metabolism / Q000821:virology; D000818:Animals; D019380:Anti-HIV Agents / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004352:Drug Resistance, Microbial / Q000235:genetics; D004359:Drug Therapy, Combination; D005838:Genotype; D006678:HIV / Q000187:drug effects* / Q000235:genetics; D017320:HIV Protease Inhibitors / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006899:Mixed Function Oxygenases / Q000378:metabolism; D009154:Mutation / Q000187:drug effects; D010641:Phenotype; D012367:RNA, Viral / Q000097:blood; D051381:Rats; D019562:Viral Load
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A